{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:51:19Z","timestamp":1790369479679,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,29]]},"DOI":"10.7759\/cureus.107970","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:45:41Z","timestamp":1777473941000},"source":"Crossref","is-referenced-by-count":1,"title":["A Review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity"],"prefix":"10.7759","author":[{"given":"Blessing T","family":"Ojinna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamede","family":"Agho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabia","family":"Channa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurdeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Obesity and overweight. (2025). Accessed. January 28, 2026: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"ref2","unstructured":"Adult obesity facts. (2024). Accessed. January 28, 2026: https:\/\/www.cdc.gov\/obesity\/adult-obesity-facts\/index.html."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcx152","article-title":"Complications of obesity","volume":"111","author":"Kinlen D","year":"2018","unstructured":"Kinlen D, Cody D, O'Shea D. Complications of obesity. QJM. 2018, 111:437-43. 10.1093\/qjmed\/hcx152","journal-title":"QJM"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2022-009773","article-title":"Economic impacts of overweight and obesity: current and future estimates for 161 countries","volume":"7","author":"Okunogbe A","year":"2022","unstructured":"Okunogbe A, Nugent R, Spencer G, Powis J, Ralston J, Wilding J. Economic impacts of overweight and obesity: current and future estimates for 161 countries. BMJ Glob Health. 2022, 7:e009773. 10.1136\/bmjgh-2022-009773","journal-title":"BMJ Glob Health"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.20410","article-title":"Direct medical costs of obesity in the United States and the most populous states","volume":"27","author":"Cawley J","year":"2021","unstructured":"Cawley J, Biener A, Meyerhoefer C, Ding Y, Zvenyach T, Smolarz BG, Ramasamy A. Direct medical costs of obesity in the United States and the most populous states. J Manag Care Spec Pharm. 2021, 27:354-66. 10.18553\/jmcp.2021.20410","journal-title":"J Manag Care Spec Pharm"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp150990","article-title":"Role of glucagon-like peptide 1 receptor agonists in management of obesity","volume":"73","author":"Isaacs D","year":"2016","unstructured":"Isaacs D, Prasad-Reddy L, Srivastava SB. Role of glucagon-like peptide 1 receptor agonists in management of obesity. Am J Health Syst Pharm. 2016, 73:1493-507. 10.2146\/ajhp150990","journal-title":"Am J Health Syst Pharm"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1593334","article-title":"Oral semaglutide for the treatment of obesity: a retrospective real-world study","volume":"16","author":"Krajnc M","year":"2025","unstructured":"Krajnc M, Kuhar N, Koceva A. Oral semaglutide for the treatment of obesity: a retrospective real-world study. Front Endocrinol (Lausanne). 2025, 16:1593334. 10.3389\/fendo.2025.1593334","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19897","article-title":"Obesity management in adults: a review","volume":"330","author":"Elmaleh-Sachs A","year":"2023","unstructured":"Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity management in adults: a review. JAMA. 2023, 330:2000-15. 10.1001\/jama.2023.19897","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14863","article-title":"Semaglutide for the treatment of overweight and obesity: a review","volume":"25","author":"Bergmann NC","year":"2023","unstructured":"Bergmann NC, Davies MJ, Lingvay I, Knop FK. Semaglutide for the treatment of overweight and obesity: a review. Diabetes Obes Metab. 2023, 25:18-35. 10.1111\/dom.14863","journal-title":"Diabetes Obes Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop FK","year":"2023","unstructured":"Knop FK, Aroda VR, do Vale RD, et al.. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023, 402:705-19. 10.1016\/S0140-6736(23)01185-6","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2025.3599","article-title":"Oral semaglutide in an East Asian population with overweight or obesity, with or without type 2 diabetes: the OASIS 2 randomized clinical trial","volume":"185","author":"Kadowaki T","year":"2025","unstructured":"Kadowaki T, Heftdal LD, Ko HJ, Overvad M, Shimomura I, Thamattoor UK, Kim KK. Oral semaglutide in an East Asian population with overweight or obesity, with or without type 2 diabetes: the OASIS 2 randomized clinical trial. JAMA Intern Med. 2025, 185:1206-17. 10.1001\/jamainternmed.2025.3599","journal-title":"JAMA Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7570\/jomes23016","article-title":"Evaluation and treatment of obesity and its comorbidities: 2022 update of clinical practice guidelines for obesity by the Korean Society for the Study of Obesity","volume":"32","author":"Kim KK","year":"2023","unstructured":"Kim KK, Haam JH, Kim BT, et al.. Evaluation and treatment of obesity and its comorbidities: 2022 update of clinical practice guidelines for obesity by the Korean Society for the Study of Obesity. J Obes Metab Syndr. 2023, 32:1-24. 10.7570\/jomes23016","journal-title":"J Obes Metab Syndr"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ23-0593","article-title":"Definition, criteria, and core concepts of guidelines for the management of obesity disease in Japan","volume":"71","author":"Ogawa W","year":"2024","unstructured":"Ogawa W, Hirota Y, Miyazaki S, et al.. Definition, criteria, and core concepts of guidelines for the management of obesity disease in Japan. Endocr J. 2024, 71:223-31. 10.1507\/endocrj.EJ23-0593","journal-title":"Endocr J"},{"key":"ref15","unstructured":"Research study looking at how well semaglutide tablets taken once daily work in Chinese adults who are above a healthy weight range (OASIS 3) (OASIS 3). (2026). Accessed. January 28, 2026: https:\/\/clinicaltrials.gov\/study\/NCT05890976."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2500969","article-title":"Oral semaglutide at a dose of 25 mg in adults with overweight or obesity","volume":"393","author":"Wharton S","year":"2025","unstructured":"Wharton S, Lingvay I, Bogdanski P, et al.. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med. 2025, 393:1077-87. 10.1056\/NEJMoa2500969","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1298347","article-title":"What are the reasons for patient preference? A comparison between oral and subcutaneous administration (Article in German)","volume":"150","author":"Quante M","year":"2012","unstructured":"Quante M, Thate-Waschke I, Schofer M. What are the reasons for patient preference? A comparison between oral and subcutaneous administration (Article in German). Z Orthop Unfall. 2012, 150:397-403. 10.1055\/s-0031-1298347","journal-title":"Z Orthop Unfall"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey WT","year":"2016","unstructured":"Garvey WT, Mechanick JI, Brett EM, et al.. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016, 22:1-203. 10.4158\/EP161365.GL","journal-title":"Endocr Pract"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1159\/000444869","article-title":"Erratum","volume":"9","year":"2016","unstructured":"Erratum. Obes Facts. 2016, 9.64. 10.1159\/000444869","journal-title":"Obes Facts"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22581","article-title":"Antiobesity medication use in 2.2 million adults across eight large health care organizations: 2009-2015","volume":"27","author":"Saxon DR","year":"2019","unstructured":"Saxon DR, Iwamoto SJ, Mettenbrink CJ, et al.. Antiobesity medication use in 2.2 million adults across eight large health care organizations: 2009-2015. Obesity (Silver Spring). 2019, 27:1975-81. 10.1002\/oby.22581","journal-title":"Obesity (Silver Spring)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2021.07.021","article-title":"Treatment of obesity: pharmacotherapy trends of office-based visits in the United States from 2011 to 2016","volume":"96","author":"Claridy MD","year":"2021","unstructured":"Claridy MD, Czepiel KS, Bajaj SS, Stanford FC. Treatment of obesity: pharmacotherapy trends of office-based visits in the United States from 2011 to 2016. Mayo Clin Proc. 2021, 96:2991-3000. 10.1016\/j.mayocp.2021.07.021","journal-title":"Mayo Clin Proc"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac195","article-title":"An updated approach to antiobesity pharmacotherapy: moving beyond the 5% weight loss goal","volume":"7","author":"Enright C","year":"2023","unstructured":"Enright C, Thomas E, Saxon DR. An updated approach to antiobesity pharmacotherapy: moving beyond the 5% weight loss goal. J Endocr Soc. 2023, 7:bvac195. 10.1210\/jendso\/bvac195","journal-title":"J Endocr Soc"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-020-04987-2","article-title":"Pharmacotherapy for obesity-trends using a population level national database","volume":"31","author":"Elangovan A","year":"2021","unstructured":"Elangovan A, Shah R, Smith ZL. Pharmacotherapy for obesity-trends using a population level national database. Obes Surg. 2021, 31:1105-12. 10.1007\/s11695-020-04987-2","journal-title":"Obes Surg"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645507","article-title":"Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide","volume":"12","author":"Gallwitz B","year":"2021","unstructured":"Gallwitz B, Giorgino F. Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide. Front Endocrinol (Lausanne). 2021, 12:645507. 10.3389\/fendo.2021.645507","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14244","article-title":"Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: the REVISE study","volume":"23","author":"Boye K","year":"2021","unstructured":"Boye K, Ross M, Mody R, Konig M, Gelhorn H. Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: the REVISE study. Diabetes Obes Metab. 2021, 23:508-19. 10.1111\/dom.14244","journal-title":"Diabetes Obes Metab"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2337\/cd22-0118","article-title":"Current understanding of sodium N-(8-[2-hydroxylbenzoyl] amino) caprylate (SNAC) as an absorption enhancer: the oral semaglutide experience","volume":"42","author":"Solis-Herrera C","year":"2024","unstructured":"Solis-Herrera C, Kane MP, Triplitt C. Current understanding of sodium N-(8-[2-hydroxylbenzoyl] amino) caprylate (SNAC) as an absorption enhancer: the oral semaglutide experience. Clin Diabetes. 2024, 42:74-86. 10.2337\/cd22-0118","journal-title":"Clin Diabetes"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-022-09735-8","article-title":"A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes","volume":"23","author":"Aroda VR","year":"2022","unstructured":"Aroda VR, Blonde L, Pratley RE. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Rev Endocr Metab Disord. 2022, 23:979-94. 10.1007\/s11154-022-09735-8","journal-title":"Rev Endocr Metab Disord"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial","volume":"318","author":"Davies M","year":"2017","unstructured":"Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OK, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017, 318:1460-70. 10.1001\/jama.2017.14752","journal-title":"JAMA"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.2438","article-title":"As Ozempic\u2019s popularity soars, here\u2019s what to know about semaglutide and weight loss","volume":"329","author":"Suran M","year":"2023","unstructured":"Suran M. As Ozempic\u2019s popularity soars, here\u2019s what to know about semaglutide and weight loss. JAMA. 2023, 329:1627-9. 10.1001\/jama.2023.2438","journal-title":"JAMA"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda VR","year":"2019","unstructured":"Aroda VR, Rosenstock J, Terauchi Y, et al.. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019, 42:1724-32. 10.2337\/dc19-0749","journal-title":"Diabetes Care"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire DK","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL, et al.. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025, 392:2001-12. 10.1056\/NEJMoa2501006","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2021-001952","article-title":"Wegovy (semaglutide): a new weight loss drug for chronic weight management","volume":"70","author":"Singh G","year":"2022","unstructured":"Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022, 70:5-13. 10.1136\/jim-2021-001952","journal-title":"J Investig Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/477134-a-review-of-the-oral-semaglutide-in-adults-with-overweight-or-obesity-oasis-trials-evaluating-oral-semaglutide-wegovy-for-chronic-weight-management-in-adults-with-overweight-or-obesity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:45:44Z","timestamp":1777473944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/477134-a-review-of-the-oral-semaglutide-in-adults-with-overweight-or-obesity-oasis-trials-evaluating-oral-semaglutide-wegovy-for-chronic-weight-management-in-adults-with-overweight-or-obesity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.107970","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,29]]}}}